AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
[{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Research Collaboration With CSL Behring","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"CSL Behring"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta, Daewoong Form Immunotherapy JV","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Secures $25 Million Series A Funding","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Kyverna Therapeutics"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$587.5 million","upfrontCash":"$17.5 million","newsHeadline":"Kyverna Therapeutics Enters into Strategic Collaboration with Gilead Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Kyverna Therapeutics"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alladapt Immunotherapeutics Secures $60 Million in Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alladapt Immunotherapeutics"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Announces \u00a327.5 M Extended Series A Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OMass Therapeutics"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sonoma bags $40M to push Tregs for autoimmune, neuro diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Sonoma Biotherapeutics"},{"orgOrder":0,"company":"Avacta Group","sponsor":"AffyXell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta and Daewoong collaborate with AffyXell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Avacta Group"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo taps Mogrify for off-the-shelf CAR-Treg project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mogrify"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclacel Pharmaceuticals Inks Collaboration With University of Edinburgh to Study CDK Inhibitors in COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"University of Edinburgh"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma Publishes Positive Results from Its Intranasal Epinephrine Preclinical Study Program In Three Peer-Reviewed Scientific Journals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bryn Pharma"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Chugai Pharmaceutical"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Qihan Biotech"},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACT Therapeutics Receives Orphan-Drug Designation for TRK-001 from the U.S. Food and Drug Administration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Tract Therapeutics"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Yangtze River Pharmaceutical Group"},{"orgOrder":0,"company":"Curexsys GmbH","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sartorius and Evotec Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Curexsys GmbH"},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medicinova"},{"orgOrder":0,"company":"Erdal","sponsor":"ActoPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erdal Can Alkoclar to Renew Antiviral License for ActoPharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Erdal"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Imcyse"},{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Continues Streamlining of Established Products with Sale of Anti-Inflammatory Drugs to Fidia Farmaceutici","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISD Immunotech Granted US and EU Patents for Novel Severe Systemic Lupus Erythematosus (SLE) Therapy Candidate ISD017","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"ISD Immunotech"},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","amount":"$11.2 million","upfrontCash":"$0.5 million","newsHeadline":"Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"HavaH Therapeutics"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taiwania Capital Joins Pool of Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Company, Windgap Medical, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Windgap Medical"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibody Treatment For MIS-C Works by Depleting Inflammatory Immune Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"National Institutes of Health"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Digitalis Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"GRO Biosciences"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bristol Myers Squibb"},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Valens Company Announces Two Strategic Agreements with PMI Mexico","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"The Valens Company"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Enzene Biosciences"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate's Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Adial Pharmaceuticals"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Nuvig Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hofseth BioCare Announces Global Innovation Partnership with Catalent to Develop Delayed-Release Formulation of OmeGo\u00ae Fish Oil","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Catalent Pharma Solutions"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Beam Therapeutics"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"EGYPT","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Minapharm Pharmaceuticals"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosenic Provides Update Regarding Current License Agreement With Phebra","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Medsenic"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Innocan Pharma Announces Closing of Second and Final Tranche of Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Innocan Pharma"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Camallergy and OnDosis Announce a Groundbreaking Partnership to Revolutionize Food Allergy Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Camallergy"},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Forward Therapeutics"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Indian firm Intas Pharma Inks New Licensing Agreement for Treating Autoimmune Diseases in 150+ Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Mabxience"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$441.8 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Licenses a New Compound as Part of its Commitment to People Living with Fibro-Inflammatory Diseases\u200b from Kyowa Kirin","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Kyowa Kirin"}]

Find Novel Immunology Drugs in Clinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fidia Farmaceutici Spa

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Divestment March 23, 2021

            Sanofi Company Banner

            AMWC Asia-TDAC

            Not Confirmed

            envelop Contact Supplier

            Details:

            Under the terms of the agreement, Boehringer Ingelheim will receive exclusive, worldwide rights from Kyowa Kirin to develop novel, first-in-class treatments for fibro-inflammatory diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: $441.8 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.

            Lead Product(s): Etanercept

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Intas Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the partnership, Camallergy's innovative therapies is combined with OnDosis' cutting-edge Dosage Manager device technology to address the challenges physicians face in offering oral immunotherapy.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: OnDosis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds will be used to advance company's portfolio of novel, next-generation, small molecule therapies for chronic immunological and inflammatory disorders, towards clinical development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing November 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds to fund the Company's pre-investigational new drug meeting regarding the human application of the Company's products, including Cannabidiol.

            Lead Product(s): Cannabidiol

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Research Capital Corporation

            Deal Size: $1.6 million Upfront Cash: Undisclosed

            Deal Type: Private Placement October 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.

            Lead Product(s): Arsenic Trioxide

            Therapeutic Area: Immunology Product Name: OATO

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Phebra

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved, under Bioventure's exclusive strategic partnership with Alvotech in the region.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bioventure Healthcare

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.

            Lead Product(s): RNA-based Medicine

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Orbital Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Nuvig is building a pipeline of differentiated protein therapeutics that specifically target affected tissues in a disease-specific manner and can be used in the context of varied but well-defined disease mechanisms.

            Lead Product(s): Protein-based Therapeutic

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novo Holdings

            Deal Size: $47.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing May 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY